Cerevel Therapeutics Holdings, Inc. (CERE) CEO Tony Coles on Q1 2022 Results - Earnings Call Transcript

Cerevel Therapeutics Holdings, Inc. (CERE) Q1 2022 Earnings Conference Call May 10, 2022 8:00 AM ET

Company Participants

Matt Calistri - Vice President of Corporate Strategy and Investor Relations
Tony Coles - Chairperson and Chief Executive Officer
Ray Sanchez - Chief Medical Officer
John Renger - Chief Scientific Officer
Mark Bodenrader - Interim Chief Financial Officer
A. Ceesay - President

Conference Call Participants

Cory Kasimov - JPMorgan
Michael Yee - Jefferies
Paul Matteis - Stifel
Douglas Tsao - H.C. Wainwright
Madhu Kumar - Goldman Sachs
Won Jung - Morgan Stanley
Esther Hong - Berenberg

Operator

Good morning and welcome to the Cerevel Therapeutics first-quarter 2022 financial results conference call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the Q&A portion of the call. Please note that this call may be recorded.

I will now hand the call over to Mr. Matt Calistri, Vice President of Corporate Strategy and Investor Relations. Please go ahead.

Matt Calistri

Thank you. Good morning, everyone. We appreciate you joining us for our first-quarter 2022 earnings call. On today's call, you'll be hearing from Dr. Tony Coles, our Chairperson and Chief Executive Officer; Dr. Ray Sanchez, our Chief Medical Officer; Dr. John Renger, our Chief Scientific Officer; and Mark Bodenrader, our Interim Chief Financial Officer; A. Ceesay, our President, will join us for Q&A. During our call today, please refer to our press release from this morning detailing our Q1 2022 performance, as well as our updated corporate presentation, both of which are available on our website. I would like to remind you that we will be making forward-looking statements that reflect our current views related to, among other things, the potential attributes and benefits of our product candidates and the format and timing of our product development activities and clinical trials. We strongly encourage you to review the information that we filed with the SEC regarding specific risks and uncertainties.